Aft Pharmaceuticals Ltd. · NZX:AFT
Aft Pharmaceuticals — H1 FY2018 Earnings Presentation
13 slides from Aft Pharmaceuticals's earnings presentation, Nov 24, 2017
Slide 1: AFT Pharmaceuticals Investor Presentation: H1 FY2018
For personal use only AFT PHARMACEUTICALS Investor Presentation: H1 FY2018 November 2017
Slide 2: Important Notice
For personal use only IMPORTANT NOTICE This presentation has been prepared by AFT Pharmaceuticals Limited (“AFT”), to provide a general overview of AFT. It is not prepared for any other purpose and must not be provided to any person other than the intended recipient. All amounts are disclosed in New
Slide 3: H1 FY2018 Highlights
For personal use only H1 FY2018 HIGHLIGHTS 124 countries that Maxigesic is licensed in – up from 110 at the end of FY2017 10 countries that Maxigesic is launched and sold in 10 number of clinical studies AFT have running in FY2018 $37.4m total income for H1 FY2018* $7.2m available cash as at 30 Sept
Slide 4: Maxigesic Update
MAXIGESIC UPDATE Nordics – launch pending Eastern Europe and Balkans – launches pending BE/LX & FR– launches pending Italy – successful launch and UK – launched sales increasing significantly For personal use only IE – launch pending Kuwait and Iraq launc pending UAE – sales doubled in second year o
Slide 5: Maxigesic Highlights
MAXIGESIC HIGHLIGHTS Additional out-licensing and distribution agreements for Maxigesic oral dose forms have been secured to increase the number of countries to 124. For personal use only Numerous Maxigesic registrations underway which are required before many launches can occur EU registrations con
Slide 6: Maxigesic: Australian growth strategy
MAXIGESIC: Australian growth strategy • Prior to the re-scheduling of codeine-based analgesics, our growth estimates were for For personal use only sales increasing in Australia from 13 to 26 million tablets in FY2018. • Codeine switch confirmed for 1st February 2018. • Codeine tablet market is now
Slide 7: NasoSURF Nebuliser: Future growth strategy
NASOSURF NEBULISER: Future growth strategy A handheld ultrasonic nasal mesh nebuliser for the Product intranasal delivery of medication and treatment of description chronic sinusitis For personal use only The NasoSURF Nebuliser has desirable features over currently marketed nebulisers, which are not
Slide 8: Revenue by Region and Channel
REVENUE BY REGION AND CHANNEL Operating revenue by region, H1 FY2018 versus H1 FY2017 • 23% growth in Group NZ$000's Half Year to 30 September H1 FY2018 % of total H1 FY2017 % of total operating revenue For personal use only Australia 20,206 55.3% 14,569 49.2% • Strong Over-the-counter growth in Aus
Slide 9: Revenue Growth
REVENUE GROWTH Operating revenue by region, H1 FY2017 – H1 FY2018 For personal use only H1 FY2017 FY2017 Annual H1 FY2018 • Australian growth 38% 20.0 40.0 20.0 • Australia now 55% of 15.0 30.0 15.0 Group revenues • New Zealand growth 5% $m $m $m 10.0 20.0 10.0 • New Zealand Prescription decline wit
Slide 10: Summary P&L
SUMMARY P&L NZ$'000's Half Year to 30 September H1 FY2018 % of H1 FY2017 % of revenue revenue For personal use only Revenue 36,561 29,787 • Margins reflect increasing Cost of Sales (22,256) 60.9% (19,018) 63.8% % of higher margin over the counter products Gross Profit 14,305 39.1% 10,769 36.2% • Sal
Slide 11: Summary Balance Sheet
SUMMARY BALANCE SHEET Unaudited Audited Unaudited NZ$'000's 31 Sept '17 31 March '17 31 Sept '16 ASSETS Current Assets Inventories 21,137 18,718 21,451 For personal use only Trade and other receivables 16,640 19,362 12,748 Cash and cash equivalents 7,197 15,980 16,054 Current income tax asset - - 19
Slide 12: Summary Cashflow Statement
SUMMARY CASHFLOW STATEMENT NZ$'000's Half Year to 30 September H1 FY2018 H1 FY2017 For personal use only • Investment into R&D and Net cash used in operating activities (7,678) (10,270) marketing spend behind Over-the-counter revenue growth Net cash used in investing activities (2,144) (686) • Finan
Slide 13: Summary of Near Term Plans
SUMMARY OF NEAR TERM PLANS Drive Increased International Sales Phased launches of Maxigesic in over 110 countries including North America For personal use only Add additional Maxigesic dose forms to the initial launches to extend sales Drive Increased Upfront Payments Further licensing agreements fo
AFT Pharmaceuticals — H1 FY2018 Earnings Presentation on 6ix